Indaptus Therapeutics' Chief Scientific Officer to Present at Donor Selection & Cell Source Summit, Highlighting Decoy Bacteria Platform for Allogeneic Immune Cell Cancer Therapy.

Indaptus Therapeutics' Chief Scientific Officer, Dr. Michael Newman, will present at the 3rd Donor Selection & Cell Source Summit. The presentation will highlight the company's Decoy bacterial platform, which uses killed, multi-immune agonist bacteria to trigger a broad immune response and address donor cell variability in allogeneic immune cell cancer therapy. The platform has the potential to enhance the potency and reproducibility of donor-derived cell therapies.